Trial Profile
An Open-label, Single-arm, Active-treatment, Efficacy and Safety Study of Canakinumab (ACZ885) Administered for at Least 48 Weeks in Japanese Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Feb 2022
Price :
$35
*
At a glance
- Drugs Canakinumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Registrational; Therapeutic Use
- Sponsors Novartis Pharmaceuticals; Novartis Pharmaceuticals Corporation
- 21 Sep 2018 Status changed from active, no longer recruiting to completed.
- 16 Jun 2018 Results presented at the 19th Annual Congress of the European League Against Rheumatism
- 14 Feb 2018 Planned End Date changed from 1 Oct 2018 to 31 Oct 2018.